Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +585.95%
#2 Phala Phala +86.06%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +27.08%
#5 Backpack Backpack +25.83%
#6 ARK ARK +24.61%
#7 Mubarak Mubarak +24.07%
#8 Aerodrome Finance Aerodrome Finance +23.48%
#9 APEX APEX +21.77%
#10 The Black Bull The Black Bull +20.57%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Rang în acțiuni #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Preț acțiune
$0.2483
Ultima sincronizare: 2026-07-31
Capitalizare de piață
$2.30M
Schimbare (1 zi)
-3.39%
Schimbare (1 an)
-89.01%
Țară
US
Tranzacționează Ensysce Biosciences, Inc. (ENSC)

Categorie

Healthcare
Raport P/S pentru Ensysce Biosciences, Inc. (ENSC)
Raport P/S la data de September 2026 TTM: 6.35
Conform celor mai recente rapoarte financiare și prețului acțiunilor Ensysce Biosciences, Inc., raportul P/S actual (TTM) este 6.35. La sfârșitul anului 2023, compania avea un P/S de 16.14.
Istoricul raportului P/S pentru Ensysce Biosciences, Inc. din 2017 până în 2026
Raport P/S la sfârșitul fiecărui an
An Raport P/S Schimbă
2026 (TTM) 6.35 132.71%
2024 2.73 -83.08%
2023 16.14 67.59%
2022 9.63 -97.61%
2021 402.60 -99.21%
2020 50.77K -60.81%
2019 129.53K 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Raport P/S pentru companii similare sau competitoare
Companie Raport P/S Diferență raport P/S Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.44 64.40%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
26.12 311.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.01 89.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.76 -40.89%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH